{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"In the Interim...","title":"A Discussion with Michael Proschan on Response-Adaptive Randomization","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/de231ccc\"></iframe>","width":"100%","height":180,"duration":2685,"description":"In this episode of \"In the Interim…\", Dr. Scott Berry and NIH’s Dr. Michael Proschan conduct a detailed discussion from opposing viewpoints on response-adaptive randomization (RAR) in clinical trials. The discussion focuses on where they agree – on the positives and negatives of RAR, and where they disagree on its scientific use. Key HighlightsPotential issues of using RAR: Potential temporal trends, unblinding, reduction in statistical efficiency in 2-arm trialsPotential benefits include improved statistical efficiency in multi-arm trials  depending on the goals (e.g. dose-finding trials).Potential unblinding of results in non-blinded trials and the need for operational excellence.Ethical and Bayesian perspectives are considered, but emphasis remains empirical.For more visit: https://www.berryconsultants.com/","thumbnail_url":"https://img.transistorcdn.com/toFATB0JXvqQXRqzUqrK1EWCJCLOA_Qvjkb5ml3q-s8/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9jM2M0/ZDE2YzA1N2FhNjkx/NDk1NDczNjYzM2E5/NjlmYS5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}